Holen Sie sich die Stockscreener-App
1.54
14.93%
0.20
Vorhandelsmarkt:
1.52
-0.02
-1.30%
Schlusskurs vom Vortag:
$1.34
Offen:
$1.38
24-Stunden-Volumen:
3.21M
Relative Volume:
1.65
Marktkapitalisierung:
$108.88M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-144.01M
KGV:
-0.384
EPS:
-4.01
Netto-Cashflow:
$-113.02M
1W Leistung:
+46.67%
1M Leistung:
+12.41%
6M Leistung:
-39.13%
1J Leistung:
-73.26%
1-Tages-Spanne:
$1.35
$1.56
1-Wochen-Bereich:
$1.0202
$1.56
52-Wochen-Spanne:
$0.8719
$6.44
Biomea Fusion Inc Stock (BMEA) Company Profile
Firmenname
Biomea Fusion Inc
Sektor
Branche
Telefon
(650) 980-9099
Adresse
1599 INDUSTRIAL ROAD, SAN CARLOS
Vergleichen Sie BMEA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.54 | 94.74M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-28 | Eingeleitet | Jefferies | Buy |
| 2025-06-03 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-10-09 | Eingeleitet | Edward Jones | Buy |
| 2024-09-27 | Hochstufung | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | Hochstufung | Truist | Hold → Buy |
| 2024-08-29 | Eingeleitet | CapitalOne | Overweight |
| 2024-06-11 | Herabstufung | Truist | Buy → Hold |
| 2024-06-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-04-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-06 | Eingeleitet | Truist | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-06-26 | Herabstufung | Jefferies | Buy → Hold |
| 2023-05-12 | Eingeleitet | Barclays | Overweight |
| 2023-03-29 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-28 | Bestätigt | H.C. Wainwright | Buy |
| 2023-02-24 | Eingeleitet | Citigroup | Buy |
| 2022-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-01-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-11 | Eingeleitet | Jefferies | Buy |
| 2021-05-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Biomea Fusion Inc Aktie (BMEA) Neueste Nachrichten
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 - The Manila Times
Biomea Fusion Highlights the Future of Menin Inhibitors and Icovamenib in Interview with Dr. Ralph DeFronzo at WCIRDC 2025 - Quiver Quantitative
Biomea Fusion : WCIRDC 2025 COVALENT 111 Week 52 final Oral Presentation - marketscreener.com
Is Biomea Fusion Inc a good long term investmentEarnings Revision Updates & High Profit Market Growth - earlytimes.in
Biomea Fusion presents COVALENT-111 study results at WCIRDC - MSN
Biomea Fusion reports durable effects of diabetes drug 9 months after dosing - Investing.com Nigeria
Biomea Fusion Showcases Durable Benefits Of Menin Inhibitor In Type-2 Diabetes - RTTNews
Biomea Fusion stock soars after durable diabetes treatment results By Investing.com - Investing.com India
Biomea Fusion stock soars after durable diabetes treatment results - Investing.com
Biomea Fusion reports durable effects of diabetes drug 9 months after dosing By Investing.com - Investing.com South Africa
Biomea Fusion Presents Promising Results for Icovamenib in Treating Type 2 Diabetes at WCIRDC 2025 - Quiver Quantitative
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - The Manila Times
Biomea Fusion Presents COVALENT-111 Study Results at the - GlobeNewswire
Is Biomea Fusion Inc. stock a buy before product launchesEarnings Recap Report & Weekly Top Gainers Alerts - Newser
BMEA Insider Trading - Quiver Quantitative
Biomea Fusion Interim CEO Increases Stake with 100,000 Shares Purchase - TradingView
BMEA: Advancing Menin and oral GLP-1 therapies for diabetes, with phase II trials and strong financial runway - TradingView
Biomea Fusion (BMEA) Stock Analysis Report | Financials & Insights - Benzinga
Biomea Fusion Director Rainer M Erdtmann Acquires 50,000 Shares - TradingView
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion to present long-term diabetes drug data at WCIRDC - Investing.com Canada
Biomea Fusion announces breakthrough data presentation at WCIRDC - Traders Union
Biomea Fusion to Present Long-Term Icovamenib Data at 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease - Quiver Quantitative
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - The Manila Times
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biomea Fusion (Nasdaq: BMEA) to present icovamenib β-cell data in insulin-deficient T2D - Stock Titan
Biomea Fusion (Nasdaq: BMEA) Grants 7,500-Share Inducement Option to New Employee - Stock Titan
Aisling Capital Management LP Purchases 1,250,000 Shares of Biomea Fusion, Inc. $BMEA - MarketBeat
Published on: 2025-11-30 10:58:22 - BỘ NỘI VỤ
Biomea Fusion Inc Stock Analysis and ForecastMoving Average Crossovers & Capital Allocation Recommendations - earlytimes.in
Why analysts remain bullish on Biomea Fusion Inc. stock2025 Market Trends & Real-Time Buy Signal Notifications - moha.gov.vn
Form 8-KCurrent report - ADVFN
Can Biomea Fusion Inc. stock outperform in 2025 bull marketTrade Entry Summary & Free Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Will Biomea Fusion Inc. stock return to pre crisis levelsJuly 2025 Catalysts & Long-Term Safe Return Strategies - BỘ NỘI VỤ
Biomea Fusion set to engage at major investor conferences - Traders Union
Biomea Fusion (BMEA) Price Target Decreased by 10.64% to 7.14 - MSN
Biomea Fusion to Participate at Upcoming Investor Conferences - Investing News Network
Biomea Fusion (Nasdaq: BMEA) plans Dec. 2–3 chats at Piper Sandler, Evercore events - Stock Titan
Is the Smart Money Moving Into 52 Weeks Entertainment Limited Institutional Buying TrendsTechnical Analysis Insights & Fast Growing Investment Ideas - earlytimes.in
Biomea Fusion downgraded to Underweight from Neutral at JPMorgan - MSN
Is Biomea Fusion Inc. a candidate for recovery playBreakout Watch & Capital Efficient Trade Techniques - newser.com
Is Biomea Fusion Inc. stock a dividend growth opportunity2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com
Why Biomea Fusion Inc. stock could be next big winnerEarnings Overview Report & Low Risk High Win Rate Picks - newser.com
Top chart patterns to watch in Biomea Fusion Inc.Earnings Miss & Real-Time Chart Breakout Alerts - newser.com
Biomea Fusion : Corporate Presentation Slidedeck 4Q 2025 - marketscreener.com
JPMorgan downgrades Biomea Fusion stock to Underweight on T2D data concerns - Investing.com Australia
Can Biomea Fusion Inc. stock rebound after recent weakness2025 Market Outlook & Proven Capital Preservation Tips - newser.com
Finanzdaten der Biomea Fusion Inc-Aktie (BMEA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):